Skip to content
Try Mental Wellness – Lifestyle
Author:
Alector, Inc.
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026